The epidemiology of antiretroviral drag resistance among drug-naive HIV-1-infected persons in 10 US cities

Hillard S. Weinstock, Irum Zaidi, Welid Heneime, Diane Bennett, J. Gerardo Garcia-Lerma, John M. Douglas, Merlons LaLota, Gordon Dickinson, Sandra Schwarcz, Lucia Torian, Deborah Wendell, Sindy Paul, Garald A. Goza, Juan Ruiz, Brian Boyett, Jonathan E. Kaplan

Research output: Contribution to journalArticle

214 Citations (Scopus)

Abstract

Background. The prevalence and characteristics of persons with newly diagnosed human immunodeficiency virus (HIV) infections with or without evidence of mutations associated with drug resistance have not been well described. Methods. Drug-naive persons in whom HIV had been diagnosed during the previous 12 months and who did not have acquired immune deficiency syndrome were sequentially enrolled from 39 clinics and testing sites in 10 US cities during 1997-2001. Genotyping was conducted from HIV-amplification products, by automated sequencing. For specimens identified as having mutations previously associated with reduced antiretroviral-drug susceptibility, phenotypic testing was performed. Results. Of 1311 eligible participants, 1082 (83%) were enrolled and successfully tested; 8.3% had reverse transcriptase or major protease mutations associated with reduced antiretroviral-drug susceptibility. The prevalence of these mutations was 11.6% among men who had sex with men but was only 6.1% and 4.7% among women and heterosexual men, respectively. The prevalence was 5.4% and 7.9% among African American and Hispanic participants, respectively, and was 13.0% among whites. Among persons whose sexual partners reportedly took antiretroviral medications, the prevalence was 15.2%. Conclusions. Depending on the characteristics of the patients tested, HIV-genotype testing prior to the initiation of therapy would identify a substantial number of infected persons with mutations associated with reduced antiretroviral-drug susceptibility.

Original languageEnglish
Pages (from-to)2174-2180
Number of pages7
JournalJournal of Infectious Diseases
Volume189
Issue number12
DOIs
StatePublished - Jun 15 2004

Fingerprint

Drug Resistance
HIV-1
Epidemiology
Mutation
HIV
Pharmaceutical Preparations
Sexual Partners
RNA-Directed DNA Polymerase
Heterosexuality
Virus Diseases
Hispanic Americans
African Americans
Acquired Immunodeficiency Syndrome
Peptide Hydrolases
Genotype
Therapeutics

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Weinstock, H. S., Zaidi, I., Heneime, W., Bennett, D., Garcia-Lerma, J. G., Douglas, J. M., ... Kaplan, J. E. (2004). The epidemiology of antiretroviral drag resistance among drug-naive HIV-1-infected persons in 10 US cities. Journal of Infectious Diseases, 189(12), 2174-2180. https://doi.org/10.1086/420789

The epidemiology of antiretroviral drag resistance among drug-naive HIV-1-infected persons in 10 US cities. / Weinstock, Hillard S.; Zaidi, Irum; Heneime, Welid; Bennett, Diane; Garcia-Lerma, J. Gerardo; Douglas, John M.; LaLota, Merlons; Dickinson, Gordon; Schwarcz, Sandra; Torian, Lucia; Wendell, Deborah; Paul, Sindy; Goza, Garald A.; Ruiz, Juan; Boyett, Brian; Kaplan, Jonathan E.

In: Journal of Infectious Diseases, Vol. 189, No. 12, 15.06.2004, p. 2174-2180.

Research output: Contribution to journalArticle

Weinstock, HS, Zaidi, I, Heneime, W, Bennett, D, Garcia-Lerma, JG, Douglas, JM, LaLota, M, Dickinson, G, Schwarcz, S, Torian, L, Wendell, D, Paul, S, Goza, GA, Ruiz, J, Boyett, B & Kaplan, JE 2004, 'The epidemiology of antiretroviral drag resistance among drug-naive HIV-1-infected persons in 10 US cities', Journal of Infectious Diseases, vol. 189, no. 12, pp. 2174-2180. https://doi.org/10.1086/420789
Weinstock HS, Zaidi I, Heneime W, Bennett D, Garcia-Lerma JG, Douglas JM et al. The epidemiology of antiretroviral drag resistance among drug-naive HIV-1-infected persons in 10 US cities. Journal of Infectious Diseases. 2004 Jun 15;189(12):2174-2180. https://doi.org/10.1086/420789
Weinstock, Hillard S. ; Zaidi, Irum ; Heneime, Welid ; Bennett, Diane ; Garcia-Lerma, J. Gerardo ; Douglas, John M. ; LaLota, Merlons ; Dickinson, Gordon ; Schwarcz, Sandra ; Torian, Lucia ; Wendell, Deborah ; Paul, Sindy ; Goza, Garald A. ; Ruiz, Juan ; Boyett, Brian ; Kaplan, Jonathan E. / The epidemiology of antiretroviral drag resistance among drug-naive HIV-1-infected persons in 10 US cities. In: Journal of Infectious Diseases. 2004 ; Vol. 189, No. 12. pp. 2174-2180.
@article{be23fd3160c64769bf647b4730c8be3e,
title = "The epidemiology of antiretroviral drag resistance among drug-naive HIV-1-infected persons in 10 US cities",
abstract = "Background. The prevalence and characteristics of persons with newly diagnosed human immunodeficiency virus (HIV) infections with or without evidence of mutations associated with drug resistance have not been well described. Methods. Drug-naive persons in whom HIV had been diagnosed during the previous 12 months and who did not have acquired immune deficiency syndrome were sequentially enrolled from 39 clinics and testing sites in 10 US cities during 1997-2001. Genotyping was conducted from HIV-amplification products, by automated sequencing. For specimens identified as having mutations previously associated with reduced antiretroviral-drug susceptibility, phenotypic testing was performed. Results. Of 1311 eligible participants, 1082 (83{\%}) were enrolled and successfully tested; 8.3{\%} had reverse transcriptase or major protease mutations associated with reduced antiretroviral-drug susceptibility. The prevalence of these mutations was 11.6{\%} among men who had sex with men but was only 6.1{\%} and 4.7{\%} among women and heterosexual men, respectively. The prevalence was 5.4{\%} and 7.9{\%} among African American and Hispanic participants, respectively, and was 13.0{\%} among whites. Among persons whose sexual partners reportedly took antiretroviral medications, the prevalence was 15.2{\%}. Conclusions. Depending on the characteristics of the patients tested, HIV-genotype testing prior to the initiation of therapy would identify a substantial number of infected persons with mutations associated with reduced antiretroviral-drug susceptibility.",
author = "Weinstock, {Hillard S.} and Irum Zaidi and Welid Heneime and Diane Bennett and Garcia-Lerma, {J. Gerardo} and Douglas, {John M.} and Merlons LaLota and Gordon Dickinson and Sandra Schwarcz and Lucia Torian and Deborah Wendell and Sindy Paul and Goza, {Garald A.} and Juan Ruiz and Brian Boyett and Kaplan, {Jonathan E.}",
year = "2004",
month = "6",
day = "15",
doi = "10.1086/420789",
language = "English",
volume = "189",
pages = "2174--2180",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - The epidemiology of antiretroviral drag resistance among drug-naive HIV-1-infected persons in 10 US cities

AU - Weinstock, Hillard S.

AU - Zaidi, Irum

AU - Heneime, Welid

AU - Bennett, Diane

AU - Garcia-Lerma, J. Gerardo

AU - Douglas, John M.

AU - LaLota, Merlons

AU - Dickinson, Gordon

AU - Schwarcz, Sandra

AU - Torian, Lucia

AU - Wendell, Deborah

AU - Paul, Sindy

AU - Goza, Garald A.

AU - Ruiz, Juan

AU - Boyett, Brian

AU - Kaplan, Jonathan E.

PY - 2004/6/15

Y1 - 2004/6/15

N2 - Background. The prevalence and characteristics of persons with newly diagnosed human immunodeficiency virus (HIV) infections with or without evidence of mutations associated with drug resistance have not been well described. Methods. Drug-naive persons in whom HIV had been diagnosed during the previous 12 months and who did not have acquired immune deficiency syndrome were sequentially enrolled from 39 clinics and testing sites in 10 US cities during 1997-2001. Genotyping was conducted from HIV-amplification products, by automated sequencing. For specimens identified as having mutations previously associated with reduced antiretroviral-drug susceptibility, phenotypic testing was performed. Results. Of 1311 eligible participants, 1082 (83%) were enrolled and successfully tested; 8.3% had reverse transcriptase or major protease mutations associated with reduced antiretroviral-drug susceptibility. The prevalence of these mutations was 11.6% among men who had sex with men but was only 6.1% and 4.7% among women and heterosexual men, respectively. The prevalence was 5.4% and 7.9% among African American and Hispanic participants, respectively, and was 13.0% among whites. Among persons whose sexual partners reportedly took antiretroviral medications, the prevalence was 15.2%. Conclusions. Depending on the characteristics of the patients tested, HIV-genotype testing prior to the initiation of therapy would identify a substantial number of infected persons with mutations associated with reduced antiretroviral-drug susceptibility.

AB - Background. The prevalence and characteristics of persons with newly diagnosed human immunodeficiency virus (HIV) infections with or without evidence of mutations associated with drug resistance have not been well described. Methods. Drug-naive persons in whom HIV had been diagnosed during the previous 12 months and who did not have acquired immune deficiency syndrome were sequentially enrolled from 39 clinics and testing sites in 10 US cities during 1997-2001. Genotyping was conducted from HIV-amplification products, by automated sequencing. For specimens identified as having mutations previously associated with reduced antiretroviral-drug susceptibility, phenotypic testing was performed. Results. Of 1311 eligible participants, 1082 (83%) were enrolled and successfully tested; 8.3% had reverse transcriptase or major protease mutations associated with reduced antiretroviral-drug susceptibility. The prevalence of these mutations was 11.6% among men who had sex with men but was only 6.1% and 4.7% among women and heterosexual men, respectively. The prevalence was 5.4% and 7.9% among African American and Hispanic participants, respectively, and was 13.0% among whites. Among persons whose sexual partners reportedly took antiretroviral medications, the prevalence was 15.2%. Conclusions. Depending on the characteristics of the patients tested, HIV-genotype testing prior to the initiation of therapy would identify a substantial number of infected persons with mutations associated with reduced antiretroviral-drug susceptibility.

UR - http://www.scopus.com/inward/record.url?scp=2942529150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942529150&partnerID=8YFLogxK

U2 - 10.1086/420789

DO - 10.1086/420789

M3 - Article

C2 - 15181563

AN - SCOPUS:2942529150

VL - 189

SP - 2174

EP - 2180

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 12

ER -